CMS

SEALSQ Unveils New Upgrades to INeS, Its Certificate Management Solution (CMS), Tailored for the Internet of Things (IoT) Domain

Retrieved on: 
Lunedì, Marzo 11, 2024

Geneva, Switzerland, March 11, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp (Nasdaq: LAES) (“SEALSQ” or “Company”), a leader in semiconductor, PKI, and Post-Quantum technology today unveiled new upgrades to INeS, its Certificate Management Solution (CMS), tailored for the IoT domain.

Key Points: 
  • Geneva, Switzerland, March 11, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp (Nasdaq: LAES) (“SEALSQ” or “Company”), a leader in semiconductor, PKI, and Post-Quantum technology today unveiled new upgrades to INeS, its Certificate Management Solution (CMS), tailored for the IoT domain.
  • This integration empowers SEALSQ to offer comprehensive IoT device management services as part of its product suite.
  • This innovation allows customers and developers to automate the management of devices and certificates, seamlessly integrating these processes with the manufacturing pipeline.
  • Employing public key cryptography and digital certificates, SEALSQ's enhanced INeS CMS for IoT offers a versatile and scalable certificate management solution.

ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy

Retrieved on: 
Venerdì, Marzo 8, 2024

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 08, 2024 (GLOBE NEWSWIRE) --  ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today highlighted two recent research publications that demonstrate the effectiveness of the unique propulsion training capabilities of the ReStore Exo-Suit for post-stroke rehabilitation.

Key Points: 
  • Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy.
  • Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded.
  • Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline.
  • The ReStore intervention group demonstrated significant improvements compared to the control group, including a 56% increase in 10-meter walking speed, and a 68% improvement in 6-minute walking distance, and the improved performance was demonstrated to persist at the post-intervention follow up assessment.

Healthcare Financial Management Association calls Patient Rights Advocate’s latest price transparency compliance report ‘irresponsible’

Retrieved on: 
Giovedì, Marzo 7, 2024

CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) -- Long an advocate for consumerism and price transparency in healthcare, the Healthcare Financial Management Association (HFMA) today called the latest report from Patient Rights Advocate (PRA) “irresponsible” and “incorrect.”

Key Points: 
  • CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) -- Long an advocate for consumerism and price transparency in healthcare, the Healthcare Financial Management Association (HFMA) today called the latest report from Patient Rights Advocate (PRA) “irresponsible” and “incorrect.”
    HFMA has maintained that to be effective, price transparency must offer clear information that is readily accessible to patients to enable them to make meaningful comparisons among providers.
  • The latest PRA report asserts that only 34.5% of the 2,000 hospitals it reviewed are compliant with the federal price transparency regulations implemented in January 2021.
  • PRA’s results contradict the Centers for Medicare & Medicaid Services (CMS) scorecard, which last scored compliance at 70% of hospitals.
  • “Beyond disagreeing with CMS’s assessment, we see PRA is consistently misinterpreting federal rules in each of its reports,” Stack said.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Marzo 6, 2024

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 and Recent Developments:
    Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
  • Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
  • Financial Results for the Fourth Quarter Ended December 31, 2023
    For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  • Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.

Simpleview and Visit Widget announce mobile apps made for tourism

Retrieved on: 
Martedì, Marzo 5, 2024

TUCSON, Ariz., March 05, 2024 (GLOBE NEWSWIRE) -- Simpleview and Visit Widget have teamed up to bring destination marketing organizations (DMOs) the ultimate mobile application and visitor journey solution.

Key Points: 
  • TUCSON, Ariz., March 05, 2024 (GLOBE NEWSWIRE) -- Simpleview and Visit Widget have teamed up to bring destination marketing organizations (DMOs) the ultimate mobile application and visitor journey solution.
  • Visit Widget is an advanced, cross-device application that creates an engaging and intuitive way for visitors to research, plan, and experience their visit.
  • “We’re thrilled to announce this strategic partnership aimed at revolutionizing the travel technology industry,” said Erich Dahlke, Co-Owner/Product Director at Visit Widget.
  • “This alliance merges the innovative prowess of Simpleview with the innovative tech of Visit Widget, promising unparalleled solutions for modern travelers.

CMS awards Noridian Medicare DME contract for third time

Retrieved on: 
Martedì, Marzo 5, 2024

FARGO, N.D., March 05, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, proudly announces the re-award of the Durable Medical Equipment (DME) Medicare Jurisdiction D (JD) contract.

Key Points: 
  • FARGO, N.D., March 05, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, proudly announces the re-award of the Durable Medical Equipment (DME) Medicare Jurisdiction D (JD) contract.
  • The Centers for Medicare & Medicaid Services (CMS) recently re-awarded Noridian the $152.8 million contract, concluding a full-and-open competitive procurement.
  • Territories, Noridian processes more than 13 million fee-for-service (FFS) claims for nearly 25,000 DME suppliers, resulting in $2.6 billion in payments for the JD contract.
  • For nearly two decades, Noridian has diligently served the suppliers and beneficiaries of JD,” said Noridian president and CEO Jon Bogenreif.

Aledade Takes Steps to Support Independent Primary Care Partners in Wake of Change Healthcare CyberAttack

Retrieved on: 
Martedì, Marzo 5, 2024

BETHESDA, MD, March 05, 2024 (GLOBE NEWSWIRE) -- Aledade , the nation’s largest network of independent primary care, today announced actions it is taking to support its network of primary care practices nationwide facing severe financial strain and other repercussions in the aftermath of the Change Healthcare cyberattack.

Key Points: 
  • BETHESDA, MD, March 05, 2024 (GLOBE NEWSWIRE) -- Aledade , the nation’s largest network of independent primary care, today announced actions it is taking to support its network of primary care practices nationwide facing severe financial strain and other repercussions in the aftermath of the Change Healthcare cyberattack.
  • “We have heard clearly from our practices that they need help to keep providing high quality patient care and their doors open,” said Farzad Mostashari, M.D., co-founder and CEO of Aledade.
  • “This is a financial emergency for a substantial number of independent practices nationwide.
  • We need decisive policy action to inject liquidity into the system until alternative payment workflows are established.

Ekso Bionics Reports Record Annual Revenue of $18.3 Million

Retrieved on: 
Lunedì, Marzo 4, 2024

SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023.

Key Points: 
  • Sales and marketing expenses for the quarter ended December 31, 2023 were $2.0 million, compared to $1.9 million for the same period in 2022.
  • Research and development expenses for the quarter ended December 31, 2023 were $1.3 million, compared to $0.9 million for the same period in 2022.
  • General and administrative expenses for the quarter ended December 31, 2023 were $2.5 million, compared to $3.2 million for the same period in 2022.
  • Revenue for the full year ended December 31, 2023 was $18.3 million, an increase of 42% compared to $12.9 million for the same period in 2022.

LifeWallet Announces a Comprehensive Settlement with 28 Affiliated Property and Casualty Insurers, Benefiting LifeWallet’s Medicare Clients Across the U.S.

Retrieved on: 
Lunedì, Marzo 4, 2024

The settlement creates an environment where Secondary Payers,2 such as health insurance plans and healthcare providers, discover Medicare liens owed to them and recover conditional payments from responsible primary plans, such as property and casualty insurers.

Key Points: 
  • The settlement creates an environment where Secondary Payers,2 such as health insurance plans and healthcare providers, discover Medicare liens owed to them and recover conditional payments from responsible primary plans, such as property and casualty insurers.
  • This will enhance LifeWallet’s ability to discover liens and recover payments owed, more quickly than through litigation.
  • It also enables LifeWallet to pursue a diversified number of entities that failed to pay liens or collected twice for the same bills, both from the insurer and LifeWallet’s assignor clients.
  • Utilizing LifeWallet’s unique payer-based knowledge, artificial intelligence (“AI”) and blockchain-based LifeChain integrations, LifeWallet has developed a comprehensive coordination of benefits clearinghouse.

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

Retrieved on: 
Lunedì, Marzo 4, 2024

NEWTOWN, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare & Medicaid Services (“CMS”) has assigned Healthcare Common Procedure Coding System (“HCPCS”) Level II codes A4593, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime” to describe the PoNS controller and A4594, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each” to describe the PoNS mouthpiece. The new HCPCS codes will be effective April 1, 2024.

Key Points: 
  • The new HCPCS codes will be effective April 1, 2024.
  • “PoNS Therapy® is life-changing for people who suffer gait impairment due to MS and we’re pleased that CMS understood the benefits of this innovative treatment by establishing HCPCS codes for both the PoNS mouthpiece and controller.
  • This marks a critical reimbursement and access milestone and provides Helius the ability to begin negotiating reimbursement with third-party payers using these unique HCPCS codes.
  • In Canada, PoNS is authorized to treat balance impairment due to MS, stroke and mild-to-moderate traumatic brain injury.